Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.54 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3702583 | 1.00 | ATM (0.56) | ATMEPHX2EPHX1SCN5ASIGMAR1 | |
| SCHEMBL471445 | 0.96 | HRH3 (0.52) | ATMEPHX2EPHX1SCN5ASIGMAR1 | |
| SCHEMBL3493021 | 0.96 | HRH3 (0.52) | ATMEPHX2EPHX1SCN5ASIGMAR1 | |
| SCHEMBL3224459 | 0.93 | ATM (0.51) | ATMEPHX2EPHX1SCN5ASIGMAR1 | |
| SCHEMBL3224457 | 0.93 | ATM (0.51) | ATMEPHX2EPHX1SCN5ASIGMAR1 | |
| Trifluoromethanesulfonic Acid SCHEMBL4261183 | 0.92 | HRH3 (0.49) | ATMEPHX2EPHX1SCN5ASIGMAR1 | |
| SCHEMBL23928877 | 0.89 | ATM (0.51) | ATMEPHX2EPHX1SCN5ASIGMAR1 | |
| SCHEMBL10258244 | 0.88 | HDAC3 (0.49) | ATMEPHX2EPHX1SCN5ASIGMAR1 | |
| SCHEMBL4509653 | 0.86 | EPHX2 (0.60) | ATMEPHX2EPHX1SCN5ASIGMAR1 | |
| SCHEMBL12180397 | 0.86 | GPR119 (0.45) | ATMEPHX2EPHX1SCN5AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023170699-A1 | TRICYCLIC SPIRO[CHROMANE-2,4'-PIPERIDIN]-4(3H)-ONE WITH 1,3,4-OXADIAZOLE LINKERS COMPOSITIONS AND PROCESS FOR PREPARATION THEREOF. | GHATPANDE NITIN (IN) | 2023-09-14 | — | — | WO | disclosed |
| EP-3294705-B1 | EBNA1 INHIBITORS AND METHODS USING SAME | WISTAR INST (US) | 2021-07-21 | — | — | EP | disclosed |
| US-10385070-B2 | Chroman-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-20 | — | — | US | disclosed |
| US-10385070-B2 | Chroman-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-20 | — | — | US | disclosed |
| EP-2675812-B1 | CHROMAN - SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-2675812-B1 | CHROMAN - SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2017-08-30 | — | — | EP | disclosed |
| WO-2017124657-A1 | BRUTON'S TYROSINE KINASE INHIBITOR HAVING SPIRAL OR BRIDGED RING STRUCTURE AND PREPARATION METHOD THEREOF | 成都倍特药业有限公司 | 2017-07-27 | — | — | WO | disclosed |
| EP-2595989-B1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2016-07-13 | — | — | EP | disclosed |
| EP-2595989-B1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2016-07-13 | — | — | EP | disclosed |
| US-9365588-B2 | Benzoxazines as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-14 | — | — | US | disclosed |
| US-7338962-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| EP-1871761-A2 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | Adolor Corporation (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070269374-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | CALIXA THERAPEUTICS, INC. | 2007-11-22 | — | — | US | disclosed |
| US-20070269374-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | CALIXA THERAPEUTICS, INC. | 2007-11-22 | — | — | US | disclosed |
| WO-2007118151-A2 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2007-10-18 | — | — | WO | disclosed |
| US-20060270695-A1 | Spirocyclic heterocyclic derivatives and methods of their use | CUBIST PHARMACEUTICALS, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006105442-A2 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2006-10-05 | — | — | WO | disclosed |
| EP-1675847-A2 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | Adolor Corporation (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20050159438-A1 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION | 2005-07-21 | — | — | US | disclosed |
| WO-2005033073-A2 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070269374-A1 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | OPRK1, OPRD1, OPRL1 | ATM 4584/4885EPHX2 808/4885EPHX1 807/4885 |
| US-20060270695-A1 | Spirocyclic heterocyclic derivatives and methods of their use | OPRK1, OPRD1, OPRL1 | ATM 4539/4885EPHX2 868/4885EPHX1 841/4885 |
| US-10385070-B2 | Chroman-spirocyclic piperidine amides as modulators of ion channels | KCNJ2, KCNJ1, KCNC1 | ATM 3881/4885EPHX2 3139/4885EPHX1 2928/4885 |
| US-20050159438-A1 | Spirocyclic heterocyclic derivatives and methods of their use | OPRK1, OPRD1, OPRL1 | ATM 4539/4885EPHX2 868/4885EPHX1 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.